Endometrioid carcinoma of the prostatic utricle

Gillatt, David; O'reilly, P. H.; Reeve, N L

doi:10.1111/j.1464-410x.1986.tb05471.x

Cited by 9 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemical markers for PSA and PAP, with better antigen retrieval methods, have answered the question of the origin of this tumour. In all but two reports [ 14, 15] the tumours have been positive for PSA and PAP. In the present study all the ductal areas were positive for both antigens, confirming the earlier reports and supporting the belief that the tumour has a prostatic histiogenesis.…”

Section: Discussionmentioning

confidence: 98%

Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study

Oxley¹,

Abbott²,

Gillatt

et al. 1998

British Journal of Urology

View full text Add to dashboard Cite

Objectives To confirm the expression of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in ductal carcinomas of the prostate, and to analyse p53, Ki67, oestrogen (ER) and androgen (AR) receptors in these tumours. Materials and methods Paraffin‐embedded samples from 12 patients with ductal carcinoma of the prostate were assessed for pattern, mitotic count and the presence of a microacinar carcinoma component. There were six pure ductal and six mixed microacinar and ductal carcinomas. Sections were stained immunohistochemically for the expression of PSA, PAP, Ki67, p53, AR and ER. Clinical data were obtained from case notes. Results Six of the ductal tumours had a papillary pattern whilst the others had a cribriform appearance. The mitotic rates in the ductal areas were high in the tumours from eight of the 12 patients. PSA and PAP immunohistochemistry were positive in all the cases. No ER immunoreactivity was found in any of the patients. Ten of the ductal tumours showed strong reactivity with AR, the other two were weakly positive; two of the tumours were strongly positive for p53 protein. All the ductal carcinomas expressed Ki67, three having >25% nuclear marking. One patient who was strongly positive for p53 and had a high Ki67 score survived only one year after diagnosis. Survival ranged from 1 to 13 years after diagnosis. Conclusion This study confirms the expression of PSA and PAP in ductal carcinomas of the prostate. The percentage of tumours expressing p53 was similar to that published for high‐grade microacinar carcinomas. The results for Ki67 suggest that ductal tumours have higher scores than microacinar tumours, but further studies are required to ascertain if this is significantly different. As half the patients with ductal tumours had co‐existent microacinar tumours, we advise transrectal prostatic biopsies in patients diagnosed with pure ductal carcinomas on transurethral resection specimens, to exclude high‐grade microacinar carcinomas. The presence of AR and the lack of ER in all the ductal carcinomas confirms that these tumours are prostatic in origin and should be treated with anti‐androgen therapy.

show abstract

Section: Discussionmentioning

confidence: 98%

Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study

Oxley¹,

Abbott²,

Gillatt

et al. 1998

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…In our series PSA and PSAP were positive in all DAC cases, while prostein was negative in 3.4% of cases. There have also been reports of PSA‐negative DAC cases indicating that, for diagnostic purposes, a combination of prostate‐specific markers should be employed.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non‐prostatic origin: a comparative study

Seipel

Samaratunga²,

Delahunt

et al. 2016

APMIS

View full text Add to dashboard Cite

Ductal adenocarcinoma of the prostate (DAC) has morphological similarities to adenocarcinomas of other organs. DAC behaves in an aggressive manner and may present with metastases. These metastases may occur at unusual sites, which itself may cause diagnostic difficulties. It is important for therapeutic decisions that a prostatic origin of these metastases be established. Our aim was to compare the protein expression of DAC and adenocarcinomas of colon, endometrium, lung, pancreas, stomach and urinary bladder. A tissue microarray was constructed using 60 DAC, 6 colonic, 7 endometrial, 7 lung, 5 pancreatic, 5 gastric, and 9 urinary bladder adenocarcinomas. Slides were stained for estrogen, progesterone and androgen receptor, prolactin, PSA, prostein, PSMA, PSAP, CDX2, lysozyme, villin, monoclonal CEA, CK7, CK20, HMWCK, p63, p504s, c‐Myc, EGFR, Ki‐67, p16, p21, p27, p53, PTEN, ERG, and PAX‐8. Androgen receptor, prostein, PSA, and PSAP were almost invariably expressed in DAC. Ki‐67‐labeling index was lower in DAC than in other adenocarcinomas. The expression patterns of intestinal markers and cytokeratins in DAC were less specific and may lead to diagnostic errors if not combined with prostate‐specific markers.

show abstract

“…This opinion is predominantly based on the fact that, since the advent of immunohistochemistry, almost all reported cases have stained positively for prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). There are two reported cases where this staining has been negative however 2,3 . Despite these exceptions to the now accepted endometrioid phenotype, the proposed origin of this lesion as a mü llerian derived tumour arising from the vestigial uterus in the male have now been all but rejected.…”

Section: Introductionmentioning

confidence: 95%

Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases

1996

View full text Add to dashboard Cite

Sixteen cases of ductal (endometrioid) carcinoma of the prostate are presented. The tumour presents in elderly men (age range 65-87 years) with haematuria or obstructive symptoms. Serum prostate specific antigen may be normal or raised. On cytoscopy, there is often an exophytic lesion in the region of the verumontanum. Histologically, two variants are recognized: papillary and cribriform, of which there were eight cases each. Eight cases consisted of pure ductal carcinoma and seven were mixed, containing a variable proportion of micro-acinar carcinoma. The associated micro-acinar carcinoma had a Gleason score of at least 5. One case of carcinosarcoma with a ductal epithelial component was also included. All cases displayed positive immunohistochemical staining for prostate specific antigen and prostatic acid phosphatase and but were negative for the basal cell marker MA903. The tumour responds well to orthodox micro-acinar carcinoma therapy and appears notably sensitive to hormonal manipulation. Follow-up of the mixed group is restricted to a maximum of 3 years. Of the eight pure cases, five patients are still alive with survival periods of 11, 8, 7, 3 and 1 years. Three patients died of intercurrent disease of which one patient survived 12 years, having received no treatment. This tumour, therefore, can be regarded as having a good prognosis.

show abstract

Endometrioid carcinoma of the prostatic utricle

Cited by 9 publications

References 3 publications

Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study

Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study

Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non‐prostatic origin: a comparative study

Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases

Contact Info

Product

Resources

About